Análise Descritiva de Parturientes e Recém-Nascidos na Maternidade: Hospital Dona Estefânia entre 2005 e 2008

Entre 2005 e 2008, registaram-se 8413 nascimentos na maternidade do Hospital Dona Estefânia (HDE), aproximadamente 8% do total nacional no mesmo período. A mortalidade fetal (0,20%) atingiu os objectivos do Plano Nacional de Saúde (PNS) para 2010 e está aos melhores niveis da União Europeia. Contudo, a percentagem média de nascimentos prétermo (8,1%) e de cesarianas (31,9%) situam-se ainda acima das metas estabelecidas pelo PNS de, respectivamente, 4,9% e 24,8%. O odds ratio de ocorrência de um índice Apgar baixo aos 5 minutos por cada 100 g de peso a menos à nascença foi de 1,35 e por cada semana a menos de gestação foi de 1,33. As parturientes tiveram em média 30,4 anos de idade, sendo 3,8% adolescentes. Cerca de 22% eram estrangeiras, valor superior à média nacional de 9%. Registou-se variabilidade entre as principais nacionalidades quanto a percentagem de partos pré-termo e de cesarianas, sendo menor nas mães chinesas. Encontrou-se significado estatístico na relação do peso à nascença com a idade de gestação,tipo de gravidez (simples/gemelar), sexo, paridade e idade da mãe. Fixando as covariáveis,uma semana de gestação a mais correspondeu, em média, a mais 176 g; um recém-nascido(RN) gémeo teve, em média, menos 381 g que um não-gémeo e um RN do sexo feminino pesou, em média, menos 48 g que um masculino. Apresentam-se tabelas de percentis de peso por sexo e idade gestacional (36-41 semanas) para os RN do HDE.

Gravidez e Anticorpos Antifosfolípidos em Doentes com Lúpus Eritematoso Sistémico. Uma Avaliação do Prognóstico

Introdução e Objectivo: A presença de anticorpos antifosfolípidos (AAF) está associada a perdas embrionárias e fetais e a outras complicações obstétricas como pré-eclâmpsia, restrição de crescimento intra-uterino e parto pré-termo. Os doentes com lúpus eritematoso sistémico (LES) com frequência possuem AAF e síndroma antifosfolípidica (SAAF) secundária. O objectivo deste estudo é avaliar comparativamente o prognóstico da gravidez em mulheres com LES na presença e na ausência de AAF. Material e Métodos:Avaliação retrospectiva de 136 gestações em mulheres com diagnóstico prévio de LES cujo seguimento foi realizado na nossa instituição entre 1993 e 2007. As grávidas com e sem AAF foram consideradas separadamente. Dados relativos a idade materna, história obstétrica passada, actividade do LES no início da gravidez, existência de nefropatia, evolução da gravidez actual, idade gestacional no parto, tipo de parto, peso do recém-nascido e a existência de complicações hipertensivas na gravidez foram analisados. Resultados: 28% (38) das grávidas com LES apresentavam AAF. Deste grupo, 28,9% tinham história de perdas fetais do segundo e/ou terceiro trimestre, em oposição a 6,12% nas doentes sem AAF(p<0,05). A avaliação da actual gravidez demonstrou uma taxa de insucesso na gravidez significativamente mais elevada na população com AAF(8,1% versus 2,1%, p<0,05). Não se verificaram diferenças significativas no peso médio do recém-nascido e na taxa de restrição intra-uterina em função da presença de AAF. A idade gestacional media no parto foi de 36,9 semanas em ambos os grupos com uma taxa idêntica de parto pré-termo. O parto ocorreu por cesariana em 47% das doentes com AAF e em 44,1% das doentes sem AAF. Conclusões:Os antecedentes obstétricos de perda fetal do 2º e 3º trimestre e a probabilidade de aborto espontâneo são mais frequentes em grávidas com LES e AAF. Nos restantes parâmetros analisados não se verificaram diferenças significativas em função da presença de AAF.

Primary Antiphospholipid Syndrome: Pregnancy Outcome in a Portuguese Population

Introduction:Women with antiphospholipid syndrome(APS) may suffer from recurrent miscarriage, fetal death, fetal growth restriction (FGR), pre-eclampsia, placental abruption, premature delivery and thrombosis. Treatment with aspirin and low molecular weight heparin (LMWH) combined with close maternal-fetal surveillance can change these outcomes. Objective: To assess maternal and perinatal outcome in a cohort of Portuguese women with primary APS. Patients and Methods: A retrospective analysis of 51 women with primary APS followed in our institution (January 1994 to December 2007). Forty one(80.4%) had past pregnancy morbidity and 35.3%(n=18) suffered previous thrombotic events. In their past they had a total of 116 pregnancies of which only 13.79 % resulted in live births. Forty four patients had positive anticardiolipin antibodies and 33 lupus anticoagulant. All women received treatment with low dose aspirin and LMWH. Results: There were a total of 67 gestations (66 single and one multiple). The live birth rate was 85.1%(57/67) with 10 pregnancy failures: seven in the first and second trimesters, one late fetal death and two medical terminations of pregnancy (one APS related). Mean (± SD) birth weight was 2837 ± 812 g and mean gestational age 37 ± 3.3 weeks. There were nine cases of FGR and 13 hypertensive complications(4 HELLP syndromes). 54.4% of the patients delivered by caesarean section. Conclusions: In our cohort, early treatment with aspirin and LMWH combined with close maternal-fetal surveillance was associated with a very high chance of a live newborn.

Factor V Leiden and Prothrombin G20210A in Portuguese Women with Recurrent Miscarriage: Is it Worthwhile to Investigate?

OBJECTIVE: To compare the prevalence of factor V Leiden (FVL) and prothrombin (PT) G20210A mutations in Portuguese women with unexplained recurrent miscarriage (RM) and a control group of parous women. MATERIALS AND METHODS: FVL and PT G20210A analysis were carried out in 100 women with three or more consecutive miscarriages and 100 controls with no history of pregnancy losses. Secondary analysis was made regarding gestational age at miscarriage (embryonic and fetal losses). RESULTS: Overall, the prevalence of FVL and PT G20210A was similar in women with RM (5 and 3%) compared with controls (5 and 1%) OR 1.36 (CI 95% 0.45-4.08). In RM embryonic subgroup, PT G20210A was observed in 1.3% of women and FVL prevalence (2.6%) was inclusively lesser than that of controls. Both polymorphisms were more prevalent in women with fetal losses than in controls, although statistical significance was not reached due to the small size of the >10 weeks' subgroup. CONCLUSION: These data indicate that neither FVL nor PT G20210A is associated with RM prior to 10 weeks of gestation. Therefore, its screening is not indicated as an initial approach in Portuguese women with embryonic RM and negative personal thromboembolic history.

Prosthetic Mitral Valve Thrombosis in Pregnancy: From Thrombolysis to Anticoagulation

INTRODUCTION: Pregnant women with mechanical prosthetic heart valves are at increased risk for valve thrombosis. Management decisions for this life-threatening complication are complex. Open-heart surgery has a very high risk of maternal mortality and fetal loss. Bleeding and embolic risks associated with thrombolytic agents, the limited efficacy of thrombolysis in certain subgroups, and a lack of experience in the setting of pregnancy raise important concerns. CASE REPORT: We report a case of mitral prosthetic valve thrombosis in early pregnancy, which was successfully treated with streptokinase. Ten years later, the same patient had an uneventful pregnancy, throughout which acenocoumarol was maintained. CONCLUSION: With this case we review the prevention (with oral anticoagulant therapy) and treatment of prosthetic valve thrombosis during pregnancy, which is important for both obstetrician and cardiologist.

The Effect of Long-Chain Polyunsaturated Fatty Acids Intake During Pregnancy on Adiposity of Healthy Full-Term Offspring at Birth

OBJECTIVE: The adjusted effect of long-chain polyunsaturated fatty acid (LCPUFA) intake during pregnancy on adiposity at birth of healthy full-term appropriate-for-gestational age neonates was evaluated. STUDY DESIGN: In a cross-sectional convenience sample of 100 mother and infant dyads, LCPUFA intake during pregnancy was assessed by food frequency questionnaire with nutrient intake calculated using Food Processor Plus. Linear regression models for neonatal body composition measurements, assessed by air displacement plethysmography and anthropometry, were adjusted for maternal LCPUFA intakes, energy and macronutrient intakes, prepregnancy body mass index and gestational weight gain. RESULT: Positive associations between maternal docosahexaenoic acid intake and ponderal index in male offspring (β=0.165; 95% confidence interval (CI): 0.031-0.299; P=0.017), and between n-6:n-3 LCPUFA ratio intake and fat mass (β=0.021; 95% CI: 0.002-0.041; P=0.034) and percentage of fat mass (β=0.636; 95% CI: 0.125-1.147; P=0.016) in female offspring were found. CONCLUSION: Using a reliable validated method to assess body composition, adjusted positive associations between maternal docosahexaenoic acid intake and birth size in male offspring and between n-6:n-3 LCPUFA ratio intake and adiposity in female offspring were found, suggesting that maternal LCPUFA intake strongly influences fetal body composition.